Want to join the conversation?
$OMC's 2Q16 revenue rose 2.1% to $3.9Bil versus $3.8Bil in 2Q15, driven by organic growth of 3.4% and revenue growth from acquisitions net of dispositions of 0.3%. Organic revenue grew in North America, the UK, the Euro Markets and Other Europe, Asia Pacific and Latin America, while organic revenue fell in the Middle East and Africa in the quarter.
Biodefense therapeutics firm $PIP announced an all-stock merger with biotech Altimmune. The respective boards of the two companies unanimously approved the merger.
$YHOO is reporting today after market close. Nobody cares about this stock.